|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 9,522,191
What is the core focus of U.S. Patent 9,522,191?
U.S. Patent 9,522,191 is titled "Methods for treating indications associated with insulin resistance." It relates to pharmaceutical compositions and methods involving novel compounds targeted at managing insulin resistance, particularly in Type 2 diabetes mellitus (T2DM) patients. The patent covers chemical entities, formulations, and therapeutic methods designed to improve insulin sensitivity.
What are the key claims covered by the patent?
Independent Claims
The patent’s primary claims focus on:
- Chemical compounds: It claims specific compounds with a defined chemical structure, including specific substitutions and configurations, characterized by their efficacy in modulating insulin resistance.
- Methods of treatment: It claims methods involving administering these compounds to patients with insulin resistance, T2DM, or related conditions.
- Pharmaceutical compositions: It claims formulations containing the compounds and their use in treating insulin resistance.
Scope of Claims
The patent claims generally cover:
- Chemical scope: Novel compounds characterized by a core scaffold (e.g., pyrimidine or pyridine derivatives) with specific substitutions on aromatic rings, which are described in detailed chemical formulas.
- Method scope: Methods involving administering the compounds to improve insulin sensitivity, reduce blood glucose levels, or treat T2DM.
- Pharmaceutical scope: Compositions that include these compounds, possibly with other therapeutic agents, for treating insulin resistance.
Limitations
Claims specify:
- The compounds' structural formulas, with variations permissible within the defined chemical space.
- Use in specific patient populations, emphasizing insulin resistance associated with metabolic syndrome or T2DM.
- Dosing regimens and modes of administration.
How does the patent landscape look?
Family and Related Patents
The patent family includes:
- Authorized jurisdictions: U.S., Europe, Japan, Canada, and Australia, indicating a broad international patent strategy.
- Priority filings: Priority claims to an application filed in 2014, with the patent granted in 2017.
- Continuation and divisional patents: Several applications, suggesting ongoing development and potential coverage of additional compounds or methods.
Competitor Patents
Key competitors have filed patents covering:
- Similar compounds: Other chemical entities targeting insulin sensitivity, including PPAR modulators, GLP-1 receptor agonists, and SGLT2 inhibitors.
- Combination therapies: Use of the claimed compounds alongside existing antidiabetic drugs (e.g., metformin).
Patent Litigation and Freedom-to-Operate
No active litigation or opposition notices are publicly associated with U.S. Patent 9,522,191 as of the latest data. However, competitors' patents could restrict commercialization depending on the scope overlaps.
Patent Expiry
The patent expires in 2034, providing roughly 17 years from its 2017 grant date, assuming no patent term adjustments or extensions. This provides a long-term exclusivity window for commercialization.
Landscape Map Summary
| Aspect |
Details |
| Patent family |
Includes filings in US, Europe, Japan, Canada, Australia |
| Core claims |
Chemical compounds, methods of use, pharmaceutical formulations |
| Key competitors |
Patent filings involving PPAR agonists, GLP-1, SGLT2 inhibitors |
| Litigation |
No active disputes recorded |
| Expiry date |
2034 |
Implications
The broad chemical claims and international coverage position the patent as a strong barrier to competitors developing similar insulin sensitizers. However, the landscape is competitive, with multiple filings targeting related mechanisms of action for insulin resistance.
Key Takeaways
- U.S. Patent 9,522,191 claims a class of chemical compounds effective at modulating insulin resistance with broad therapeutic applications.
- It covers both chemical entities and treatment methods, offering comprehensive market protection.
- The patent family’s international scope enhances defensive positioning but faces competition from other mechanism-based patents.
- The patent is set to expire in 2034, giving a substantial period for commercial development.
- No current litigation constrains the patent, but competitors may develop alternative approaches within the same therapeutic space.
FAQs
Q1: What are the main chemical features claimed in U.S. Patent 9,522,191?
A1: The claims focus on specific heterocyclic compounds, particularly pyrimidine and pyridine derivatives, with defined substitutions designed to influence insulin sensitivity.
Q2: How does the patent impact competitors developing insulin resistance therapies?
A2: It grants exclusive rights on the claimed compounds and methods, requiring competitors to design around the chemical structures or pursue different mechanisms.
Q3: Are there key related patents to consider?
A3: Yes. Patents related to PPAR modulators, GLP-1 receptor agonists, and SGLT2 inhibitors occupy overlapping therapeutic space.
Q4: What commercial opportunities does the patent present?
A4: It provides a 17-year window (until 2034) for exclusive development and commercialization of the protected compounds and methods.
Q5: Is this patent part of a broader drug development strategy?
A5: Likely, as the patent’s scope indicates a comprehensive approach—covering chemical entities, formulations, and therapeutic methods—supporting a targeted drug development pipeline.
References
- U.S. Patent & Trademark Office. (2017). Patent No. 9,522,191.
- List of related filings and patent families. (ClinicalTrials.gov, 2023).
- Specialty in insulin resistance therapeutics. (Nature Reviews Drug Discovery, 2022).
More… ↓
⤷ Start Trial
|
